Paula Alves, CEO
Paula Alves is the CEO of iBET, the Head of the Animal Cell Technology Unit and Professor at the NOVA University (ITQB and FCT). She received her Ph.D. at Biochemical Engineering from the NOVA University of Lisbon in 2001 and her B.S in Biochemistry from the Sciences Faculty of the University of Lisbon in 1991. Professor Alves research group integrates cell metabolism understanding with biochemical engineering for the improvement of bioprocesses efficiency and is also focused at developing new tools and technologies for pre-clinical research. The Unit she coordinates uses Animal Cell Technology for research and development in particular for (i) production of complex biopharmaceuticals such as viral vectors, vaccines and recombinant proteins (ii) development of 3D culture systems for toxicity testing using primary cells and stem cells in bioreactors (iii) expand systems biology approaches to organize the complexity of the processes involved in the research described in (i) and (ii). She is currently the President of the ESACT, the European Society for Animal Cell Technology and Member of the IMI Scientific Council (Innovative Medicines Initiative) and of EURL-ECVAM (EU Reference Laboratory for Alternatives to Animal Testing). She was a member of the Advisory Board of Horizon 2020 Societal Challenge 1 - European Commission between 2013 and 2018. Paula Alves has published over 230 papers and 32 book chapters. She supervised 29 PhD students, 10 post-doc and several master theses.
Manuel Carrondo, Vice-President and founder of iBET
Manuel Carrondo is Full Professor of Chemical and Biochemical Engineering at the Faculty of Sciences and Technology, NOVA University of Lisbon. Manuel Carrondo has extensive management experience in the biotechnology sector and heads iBET’s Business Development. His key areas of interest include Animal Cell Technology and its application for human and animal health; Therapeutic and diagnostic recombinant proteins, including fusion proteins; virus like particles and pseudo viruses as vaccination agents and viruses (retro-, adeno-, lenti-) as deliverables for gene therapy; cell therapies and stem cells and cGMP pilot plant scale-up and production development of biopharmaceuticals. He is Advisory Board Member of CEVEC Pharmaceuticals, PBS Biotech, CNIC - Spanish National Center for Cardiovascular Research Carlos III, Masthercells - Manufacturing Synergies for Therapeutic Cells, Alloksys - Life Sciences BV, and IBMT - Fraunhofer Institute for Biomedical Engineering and GenIbet Biopharmaceuticals. OECD - Portuguese representative to the Working Party on Biotechnology, Nanotechnology and Converging Technologies. Manuel Carrondo has published over 230 papers and supervised 35 PhD students.